Industry: Pharmaceuticals, Biotechnology
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases. Founded in 2002, Reata is developing five distinct classes of cancer drugs licensed from leading academic institutions. The company has three drugs in Phase 1 clinical development: RTA 744 for primary brain cancers; RTA 402 for solid tumors and lymphoid malignancies; and RTA 401 for leukemias and solid tumors. Reata is matching its clinical and preclinical drug development programs with a best-of-class drug discovery platform to identify small molecule chaperones that can induce proper folding of p53, SOD, and Tau, misfolded proteins that are involved in cancer and neurodegenerative disease. ( www.reatapharma.com )
Reata Pharmaceuticals , Inc.
2801 Gateway Drive, Suite 150
Irving, Texas 75063
USA
Tel: (972) 865-2200
Fax: (214) 722-0867